- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01503125
Giant Axonal Neuropathy Natural History Study
Clinical Study of Giant Axonal Neuropathy
Giant Axonal Neuropathy (GAN) is a devastating and rare childhood disease. Children with GAN develop increasing muscle weakness, impaired sensation, and at times mental retardation. GAN starts in infancy, leads to significant disability, and typically leads to death within the first 30 years of life. GAN is caused by a defect in the "gigaxonin" (GAN) gene, resulting in pathologically enlarged and dysfunctional nerves. Currently, there is no effective therapy. To find out what medications can help patients with GAN, the investigators have to conduct clinical trials. In this study, the investigators propose to prepare for future clinical trials and will invite GAN patients to join our research effort.
The investigators will examine them regularly to better understand their disease. The visits will include questions, a physical exam, blood drawing, a lumbar puncture, and a skin biopsy. The visits will also include tests that assess the electrical conductivity of the patients' nerves as well as a test to measure the patients' brain wave activity. In addition, the investigators will be performing tests to evaluate the patients' motor function, their vision, and thinking ability. Identifying an effective GAN treatment is very important because there is currently none. Clinical trials are the only way to decide whether a new treatment works in GAN patients or not.
With the future objective of conducting clinical trials in GAN, the proposed project has three specific aims. The first is to plan for clinical trials by developing reliable outcome measures, and establishing the infrastructure needed to carry out efficient clinical trials. The second is to further characterize the patient population from a clinical and molecular point of view, and the third aim is to utilize the information gathered in this study to further pre-clinical GAN drug development to select candidate drugs.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Pediatric Neuromuscular Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of Giant Axonal Neuropathy.
- Documentation of the presence of a mutation in the GAN gene as determined by gene sequencing from a CAP/CLIA certified laboratory or an equivalent organization.
- Parents or if applicable subjects must give informed consent must be capable of complying with the study procedures.
- Willing and able to comply with all protocol requirements and procedures.
Exclusion Criteria:
- Unwilling or unable to travel to Columbia University Medical Center.
- Unstable medical condition precluding participation.
- Significant respiratory compromise that would interfere with safe travel to site of evaluation.
- Having a contraindication to the MRI safety requirements, including pacemaker or other implanted electrical device, brain stimulator, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), implanted delivery pump, shrapnel fragments, or history of claustrophobia.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Gross Motor Function Measure (GMFM)
Time Frame: Up to 24 months
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nerve Conduction Study (NCS)/Motor Unit Number Estimation (MUNE)
Time Frame: Up to 24 months
|
Up to 24 months
|
Somatosensory Evoked Potential (SSEP)
Time Frame: Up to 24 months
|
Up to 24 months
|
Brainstem Auditory Evoked Response (BAER)
Time Frame: Up to 24 months
|
Up to 24 months
|
Pulmonary Function Testing (PFT)/Forced Vital Capacity (FVC)
Time Frame: Up to 24 months
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Nervous System Malformations
- Polyneuropathies
- Hereditary Sensory and Motor Neuropathy
- Peripheral Nervous System Diseases
- Giant Axonal Neuropathy
Other Study ID Numbers
- AAAI4500
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Giant Axonal Neuropathy
-
Taysha Gene Therapies, Inc.National Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingGene Transfer | Giant Axonal NeuropathyUnited States
-
Ludwig-Maximilians - University of MunichCompletedPain | Axonal Change, NeuronalGermany
-
Aarhus University HospitalUniversity of Southern DenmarkCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy | Hereditary Axonal Neuropathy | Hereditary Demyelinated Neuropathy | Polyneuropathy, Inflammatory Demyelinating, ChronicDenmark, Germany
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Diffuse Axonal Brain InjuryBrazil
-
European Organisation for Research and Treatment...AmgenTerminatedBone Giant Cell TumorSpain, United Kingdom, Italy, Netherlands
-
Deciphera Pharmaceuticals LLCActive, not recruitingTenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, Diffuse | Tenosynovial Giant Cell Tumor, LocalizedNorway, United States, France, Spain, Hong Kong, Netherlands, Italy, Germany, Australia, United Kingdom, Canada, Poland, Switzerland
-
Vanderbilt UniversityUCB PharmaCompletedChronic Idiopathic Axonal PolyneuropathyUnited States
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Deciphera Pharmaceuticals LLCActive, not recruitingAdvanced Malignant Neoplasm | Tenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, DiffuseUnited States, France, Spain, United Kingdom, Netherlands, Canada, Italy, Australia, Poland
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell TumorUnited States, Spain, Taiwan, Australia, Hungary, Italy, Netherlands